Immunsuppression und Impferfolg

Markiert sind besonders wichtige Quellen.

• SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

  nature.com, hinzugefügt am 05.08.2023, wichtige Quelle

• Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

  nature.com, hinzugefügt am 10.04.2023, wichtige Quelle

• Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients

  jamanetwork.com, hinzugefügt am 27.05.2022, wichtige Quelle

• Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)

  medrxiv.org, hinzugefügt am 22.11.2021, wichtige Quelle

• Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

  thelancet.com, hinzugefügt am 19.11.2021, wichtige Quelle

• STIKO-Empfehlung zur COVID-19-Impfung: Personen mit Immundefizienz

  rki.de, hinzugefügt am 12.10.2021, wichtige Quelle

• Study identifies predictors of COVID-19 vaccine response in rituximab-treated patients

  rheumatology.medicinematters.com, hinzugefügt am 03.10.2021, wichtige Quelle

• STIKO-Empfehlung zur COVID-19-Impfung bei Personen mit Immundefizienz und die dazugehörige wissenschaftliche Begründung

  rki.de, hinzugefügt am 03.10.2021, wichtige Quelle

• Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

  thelancet.com, hinzugefügt am 29.09.2021, wichtige Quelle

• SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity FREE

  ard.bmj.com, hinzugefügt am 03.08.2021, wichtige Quelle

• Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesFREE

  acpjournals.org, hinzugefügt am 23.06.2021, wichtige Quelle

• SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity

  nature.com, hinzugefügt am 07.04.2023

• Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

  thelancet.com, hinzugefügt am 30.12.2022

• Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer

  jamanetwork.com, hinzugefügt am 30.12.2022

• Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study

  bmcinfectdis.biomedcentral.com, hinzugefügt am 14.11.2022

• SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

  jnnp.bmj.com, hinzugefügt am 26.10.2022

• COVID-19-Auffrisch­impfung: Humorale Immunantwort bei Krebspatienten von Behandlungsart abhängig

  aerzteblatt.de, hinzugefügt am 26.10.2022

• Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States

  jamanetwork.com, hinzugefügt am 24.06.2022

• Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

  thelancet.com, hinzugefügt am 25.05.2022

• Immunological findings in a group of individuals who were non-responders to standard two-dose SARS-CoV-2 vaccines

  biorxiv.org, hinzugefügt am 09.05.2022

• Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

  sciencedirect.com, hinzugefügt am 11.04.2022

• Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

  sciencedirect.com, hinzugefügt am 11.04.2022

• T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

  sciencedirect.com, hinzugefügt am 22.03.2022

• Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

  thelancet.com, hinzugefügt am 22.03.2022

• Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

  jamanetwork.com, hinzugefügt am 11.03.2022

• Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects

  jaci-inpractice.org, hinzugefügt am 08.03.2022

• Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects

  jaci-inpractice.org, hinzugefügt am 08.03.2022

• Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination

  wwwnc.cdc.gov, hinzugefügt am 06.03.2022

• COVID Auffrischimpfung für Menschen mit Rheuma

  dgrh.de, hinzugefügt am 21.02.2022

• Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

  cell.com, hinzugefügt am 19.02.2022

• Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy

  frontiersin.org, hinzugefügt am 17.02.2022

• Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

  thelancet.com, hinzugefügt am 11.01.2022

• SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

  jamanetwork.com, hinzugefügt am 11.01.2022

• Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

  cell.com, hinzugefügt am 11.01.2022

• Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

  sciencedirect.com, hinzugefügt am 29.12.2021

• Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment

  exphem.org, hinzugefügt am 29.12.2021

• Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

  jamanetwork.com, hinzugefügt am 29.12.2021

• Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

  thelancet.com, hinzugefügt am 29.12.2021

• SARS-CoV-2: Nierentrans­plantierte reagieren nur schwach auf Booster

  aerzteblatt.de, hinzugefügt am 23.12.2021

• Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

  eventpilot.us, hinzugefügt am 18.12.2021

• COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine

  acrabstracts.org, hinzugefügt am 18.12.2021

• Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study

  academic.oup.com, hinzugefügt am 18.12.2021

• „Mehrere Impfversuche bei initialen Non-Respondern machen“

  aerzteblatt.de, hinzugefügt am 18.12.2021

• Schlechtes Ansprechen auf Coronaimpfung vor allem bei Non-Hodgkin-Lymphom und aktiver Therapie

  aerzteblatt.de, hinzugefügt am 17.12.2021

• Undetectable SARS-CoV-2 active adaptive immunity—post-vaccination or post-COVID-19 severe disease—after immunosuppressants use

  casereports.bmj.com, hinzugefügt am 09.12.2021

• Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant

  jamanetwork.com, hinzugefügt am 09.12.2021

• Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

  cell.com, hinzugefügt am 07.12.2021

• Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

  jamanetwork.com, hinzugefügt am 07.12.2021

• T cells step up after SARS-CoV-2 vaccination with B cell depletion

  nature.com, hinzugefügt am 06.12.2021

• Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

  tandfonline.com, hinzugefügt am 01.12.2021

• A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients

  medrxiv.org, hinzugefügt am 29.11.2021

• Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant

  jamanetwork.com, hinzugefügt am 25.11.2021

• Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases

  thelancet.com, hinzugefügt am 25.11.2021

• Impfansprechen von Dialysepatienten auf COVID-19-Impfstoffe

  aerzteblatt.de, hinzugefügt am 25.11.2021

• SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

  jamanetwork.com, hinzugefügt am 20.11.2021

• Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-α inhibitors

  cell.com, hinzugefügt am 20.11.2021

• Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis

  thelancet.com, hinzugefügt am 19.11.2021

• mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

  thelancet.com, hinzugefügt am 19.11.2021

• Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

  thelancet.com, hinzugefügt am 19.11.2021

• Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

  jhoonline.biomedcentral.com, hinzugefügt am 19.11.2021

• Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

  thelancet.com, hinzugefügt am 19.11.2021

• Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab -

  mashupmd.com, hinzugefügt am 19.11.2021

• Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab- treated patients: Comment on article of Simon et al

  onlinelibrary.wiley.com, hinzugefügt am 19.11.2021

• COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications

  spcare.bmj.com, hinzugefügt am 19.11.2021

• Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab

  acrabstracts.org, hinzugefügt am 19.11.2021

• COVID-19 vaccine response factors identified in rituximab-treated patients

  rheumatology.medicinematters.com, hinzugefügt am 19.11.2021

• Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients

  pubmed.ncbi.nlm.nih.gov, hinzugefügt am 19.11.2021

• Rituximab Frequency Could Influence Rheumatic Patient Response to COVID-19 Vaccines

  hcplive.com, hinzugefügt am 19.11.2021

• Rituximab Linked to Worse COVID-19 Vaccine Response than Immunosuppressants

  hcplive.com, hinzugefügt am 19.11.2021

• Covid-Impfung für Krebspatienten: Neue Daten belegen Wirksamkeit

  healthcare-in-europe.com, hinzugefügt am 19.11.2021

• COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

  thelancet.com, hinzugefügt am 19.11.2021

• COVID-19: mRNA-Impfstoffe bei abwehrgeschwächten Patienten schwächer wirksam

  aerzteblatt.de, hinzugefügt am 06.11.2021

• Diese Gruppe Menschen Wird Von MRna Impfstoffen Wie BionTech Wohl Nicht Ausreichend Geschützt!

  androidkosmos.de, hinzugefügt am 05.11.2021

• Uneven Covid-19 vaccine efficacy in blood cancers mean masks to stay

  clinicaltrialsarena.com, hinzugefügt am 04.11.2021

• Immunization of immunocompromised persons: Canadian Immunization Guide

  canada.ca, hinzugefügt am 01.11.2021

• Vaccines and the immunosuppressed

  covid.joinzoe.com, hinzugefügt am 01.11.2021

• Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

  news-medical.net, hinzugefügt am 01.11.2021

• Neuartiger Impfstoff gegen SARS-CoV-2 speziell für Patienten mit Krebserkrankungen und Immunschwäche in Erprobung

  medizin.uni-tuebingen.de, hinzugefügt am 01.11.2021

• COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

  thelancet.com, hinzugefügt am 29.10.2021

• Was, wenn auch die dritte Corona-Impfung nicht wirkt?

  t-online.de, hinzugefügt am 25.10.2021

• Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease

  thelancet.com, hinzugefügt am 18.10.2021

• Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases

  jamanetwork.com, hinzugefügt am 16.10.2021

• WHO-Beirat empfiehlt dritte Coronaimpfdosis für Immungeschwächte

  aerzteblatt.de, hinzugefügt am 12.10.2021

• Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

  thelancet.com, hinzugefügt am 06.10.2021

• Ema empfiehlt Booster-Impfungen für Immungeschwächte

  spiegel.de, hinzugefügt am 05.10.2021

• Delayed Kinetics of IgG, but not IgA, Anti-spike Antibodies in Transplant Recipients following SARS-CoV-2 Infection

  jasn.asnjournals.org, hinzugefügt am 05.10.2021

• COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

  thelancet.com, hinzugefügt am 05.10.2021

• Ohne B-Zellen zum Impferfolg

  twincore.de, hinzugefügt am 03.10.2021

• Covid-19: Eingeschränkter Impferfolg nach Antikörpertherapie

  idw-online.de, hinzugefügt am 03.10.2021

• Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

  nature.com, hinzugefügt am 03.10.2021

• COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab

  the-rheumatologist.org, hinzugefügt am 03.10.2021

• Sind SARS-CoV-2-reaktive T‑Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?

  link.springer.com, hinzugefügt am 03.10.2021

• Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

  thelancet.com, hinzugefügt am 03.10.2021

• Eingeschränkter Impferfolg nach Antikörpertherapie

  unibe.ch, hinzugefügt am 03.10.2021

• Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

  nature.com, hinzugefügt am 02.10.2021

• Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

  nature.com, hinzugefügt am 02.10.2021

• Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

  jamanetwork.com, hinzugefügt am 02.10.2021

• Reduced magnitude and durability of humoral immune responses by COVID-19 mRNA vaccines among older adults

  medrxiv.org, hinzugefügt am 29.09.2021

• Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine

  thelancet.com, hinzugefügt am 29.09.2021

• QCovid® risk calculator

  bmjsept2021.qcovid.org, hinzugefügt am 27.09.2021

• Neue Auswertungen aus Großbritannien Welche Menschen trotz Corona-Impfung schwer erkranken

  t-online.de, hinzugefügt am 27.09.2021

• Anti-CD20-Antikörpertherapie ist keine Kontraindikation für COVID-19-Impfung!

  ncbi.nlm.nih.gov, hinzugefügt am 24.09.2021

• SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity FREE

  ard.bmj.com, hinzugefügt am 24.09.2021

• Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

  jamanetwork.com, hinzugefügt am 20.09.2021

• Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

  cell.com, hinzugefügt am 20.09.2021

• Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

  cell.com, hinzugefügt am 20.09.2021

• Rituximab und SARS-CoV-Impfung: Mit den ersten peripheren B-Zellen kommt auch die Antikörperantwort

  dgn.org, hinzugefügt am 20.09.2021

• SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

  ard.bmj.com, hinzugefügt am 20.09.2021

• Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination

  onlinelibrary.wiley.com, hinzugefügt am 20.09.2021

• COVID-19 vaccine failure in a patient on rituximab therapy

  academic.oup.com, hinzugefügt am 20.09.2021

• Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

  academic.oup.com, hinzugefügt am 19.09.2021

• SARS-CoV-2-Impfung wirkt bei Patienten mit Immun­schwächekrankheiten schwächer

  aerzteblatt.de, hinzugefügt am 15.09.2021

• COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

  thelancet.com, hinzugefügt am 15.09.2021

• Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2FREE

  acpjournals.org, hinzugefügt am 15.09.2021

• Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

  thelancet.com, hinzugefügt am 15.09.2021

• Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

  cancerdiscovery.aacrjournals.org, hinzugefügt am 15.09.2021

• SARS-CoV-2-Impfung wirkt bei Patienten mit Immun­schwächekrankheiten schwächer

  aerzteblatt.de, hinzugefügt am 14.09.2021

• Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with ANCA vasculitis

  kidney-international.org, hinzugefügt am 14.09.2021

• Pandemie erfordert Neubewertung der antirheumatischen Therapeutika

  rosenfluh.ch, hinzugefügt am 14.09.2021

• Ohne B-Zellen zum Impferfolg

  twincore.de, hinzugefügt am 14.09.2021

• SARS-CoV-2-Impfung wirkt bei Patienten mit Immun­schwächekrankheiten schwächer

  aerzteblatt.de, hinzugefügt am 28.08.2021

• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

  thelancet.com, hinzugefügt am 26.08.2021

• Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

  thelancet.com, hinzugefügt am 26.08.2021

• Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

  sciencedirect.com, hinzugefügt am 26.08.2021

• Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

  papers.ssrn.com, hinzugefügt am 26.08.2021

• COVID-19 vaccine response in people with multiple sclerosis

  medrxiv.org, hinzugefügt am 24.08.2021

• Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

  fda.gov, hinzugefügt am 14.08.2021

• Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines

  medrxiv.org, hinzugefügt am 03.08.2021

• Are Immunocompromised Patients Left Out by COVID Vaccines?

  cuimc.columbia.edu, hinzugefügt am 03.08.2021

• Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

  thelancet.com, hinzugefügt am 28.07.2021

• Transplant patients’ higher rate of COVID-19 breakthroughs boosts case for booster vaccines

  sciencemag.org, hinzugefügt am 27.07.2021

• The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

  thelancet.com, hinzugefügt am 20.07.2021

• Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

  nejm.org, hinzugefügt am 20.07.2021

• CDC warns Covid-19 vaccines might not protect people who are immunocompromised

  edition.cnn.com, hinzugefügt am 19.07.2021

• Auch ohne B-Zellen zum Impferfolg gegen COVID-19

  innovationorigins.com, hinzugefügt am 17.07.2021

• CDC advisers to consider additional coronavirus dose for immunocompromised patients

  washingtonpost.com, hinzugefügt am 17.07.2021

• Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

  immunology.sciencemag.org, hinzugefügt am 09.07.2021

• Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients

  immunology.sciencemag.org, hinzugefügt am 09.07.2021

• The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

  thelancet.com, hinzugefügt am 09.07.2021

• SARS-CoV-2: Einige Krebstherapeutika machen Impfung unwirksam

  aerzteblatt.de, hinzugefügt am 09.07.2021

• Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis

  medrxiv.org, hinzugefügt am 03.07.2021

• The Challenge of Covid-19 Vaccines for the Immunosuppressed

  wired.com, hinzugefügt am 30.06.2021

• Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

  acpjournals.org, hinzugefügt am 30.06.2021

• Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

  jamanetwork.com, hinzugefügt am 30.06.2021

• Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

  jamanetwork.com, hinzugefügt am 30.06.2021

• Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients

  kireports.org, hinzugefügt am 30.06.2021

• COVID-19 Vaccine in the Immunocompromised Study (CoVICS)

  upmc.com, hinzugefügt am 30.06.2021

• Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesFREE

  acpjournals.org, hinzugefügt am 30.06.2021

• Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

  medrxiv.org, hinzugefügt am 30.06.2021

• Seasonal influenza vaccine in immunocompromised persons

  pubmed.ncbi.nlm.nih.gov, hinzugefügt am 30.06.2021

• COVID-19 vaccine responses to be studied in people with immune deficits

  nih.gov, hinzugefügt am 30.06.2021

• Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

  nejm.org, hinzugefügt am 30.06.2021

• Protecting The Immuno-Compromised Against COVID Could Be Key To Ending The Pandemic

  npr.org, hinzugefügt am 30.06.2021

• Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK

  thelancet.com, hinzugefügt am 30.06.2021

• Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

  cell.com, hinzugefügt am 30.06.2021

• Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

  cell.com, hinzugefügt am 30.06.2021

• The Challenge of Covid-19 Vaccines for the Immunosuppressed

  wired.com, hinzugefügt am 23.06.2021

• Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

  jamanetwork.com, hinzugefügt am 23.06.2021

• Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

  jamanetwork.com, hinzugefügt am 23.06.2021

• Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients

  kireports.org, hinzugefügt am 23.06.2021

• Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

  medrxiv.org, hinzugefügt am 23.06.2021

• COVID-19 Vaccine in the Immunocompromised Study (CoVICS)

  upmc.com, hinzugefügt am 23.06.2021

• Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases FREE

  ard.bmj.com, hinzugefügt am 23.06.2021

• Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesFREE

  acpjournals.org, hinzugefügt am 23.06.2021

• High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases FREE

  ard.bmj.com, hinzugefügt am 23.06.2021

• Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

  medrxiv.org, hinzugefügt am 23.06.2021

• Seasonal influenza vaccine in immunocompromised persons

  pubmed.ncbi.nlm.nih.gov, hinzugefügt am 23.06.2021

• COVID-19 vaccine responses to be studied in people with immune deficits

  nih.gov, hinzugefügt am 23.06.2021

• Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

  acpjournals.org, hinzugefügt am 20.06.2021

• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

  thelancet.com, hinzugefügt am 20.06.2021

• Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

  immunology.sciencemag.org, hinzugefügt am 20.06.2021

• Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer

  cell.com, hinzugefügt am 20.06.2021

• SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

  ard.bmj.com, hinzugefügt am 14.06.2021

• 'Breakthrough' COVID Infections May Be Common in Vaccinated Transplant Patients

  usnews.com, hinzugefügt am 09.06.2021

• SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

  ard.bmj.com, hinzugefügt am 27.05.2021

• Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

  ard.bmj.com, hinzugefügt am 27.05.2021

• Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’

  ard.bmj.com, hinzugefügt am 27.05.2021

• Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al FREE

  ard.bmj.com, hinzugefügt am 27.05.2021

• Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients

  cancerdiscovery.aacrjournals.org, hinzugefügt am 22.05.2021

• There are more immunocompromised Americans than we think, and that’s a problem with COVID-19 vaccines

  popsci.com, hinzugefügt am 22.05.2021

• Covid vaccines may not protect people with immune disorders. NIH trial seeks answers.

  nbcnews.com, hinzugefügt am 15.05.2021

• Teils mehrere Impfversuche Impfantwort bei Autoimmunkranken gestört

  n-tv.de, hinzugefügt am 13.05.2021

• Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease

  medrxiv.org, hinzugefügt am 13.05.2021

• Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

  medrxiv.org, hinzugefügt am 12.05.2021

• Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2

  frontiersin.org, hinzugefügt am 12.05.2021

• Warum sich Leukämie-Patienten gegen Covid impfen lassen sollen

  presseportal.de, hinzugefügt am 11.05.2021

• Vaccination Against COVID 'Does Not Mean Immunity' For People With Organ Transplants

  npr.org, hinzugefügt am 08.05.2021

• COVID-19: Organtransplantierte auch nach 2. Impfdosis nicht sicher geschützt

  aerzteblatt.de, hinzugefügt am 08.05.2021

• Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

  jamanetwork.com, hinzugefügt am 06.05.2021

• Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

  sciencedirect.com, hinzugefügt am 04.05.2021

• Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors.

  sciencedirect.com, hinzugefügt am 04.05.2021

• Some patients do not develop immunity after covid vaccination

  sundhedspolitisktidsskrift.dk, hinzugefügt am 04.05.2021

• Auch STIKO empfiehlt, bei eingeschränkter Immunabwehr zu impfen

  pharmazeutische-zeitung.de, hinzugefügt am 02.05.2021

• Relief and worry for immune-suppressed people

  science.sciencemag.org, hinzugefügt am 30.04.2021

• COVID19 Impfung bei MS-Patienten mit Immuntherapien – neue Daten aus Israel

  ms-docblog.de, hinzugefügt am 29.04.2021

• In-Depth: A potential vaccine substitute for people with compromised immune systems?

  10news.com, hinzugefügt am 29.04.2021

• COVID-19 vaccines may not offer complete protection for people with compromised immune systems

  abcnews.go.com, hinzugefügt am 29.04.2021

• Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

  thelancet.com, hinzugefügt am 28.04.2021

• COVID-19 Vaccination of Immunocompromised Patients Manual

  lci.rivm.nl, hinzugefügt am 22.04.2021

• ESMO STATEMENTS FOR VACCINATION AGAINST COVID-19 IN PATIENTS WITH CANCER

  esmo.org, hinzugefügt am 22.04.2021

• Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic

  thelancet.com, hinzugefügt am 22.04.2021

• More advice on vaccines for immunocompromised patients

  www1.racgp.org.au, hinzugefügt am 22.04.2021

• Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

  thelancet.com, hinzugefügt am 21.04.2021

• Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment

  ncbi.nlm.nih.gov, hinzugefügt am 19.04.2021

• Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases

  ncbi.nlm.nih.gov, hinzugefügt am 19.04.2021

• COVID-19 vaccination and antirheumatic therapy

  ncbi.nlm.nih.gov, hinzugefügt am 19.04.2021

• Comment on “An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology”

  ncbi.nlm.nih.gov, hinzugefügt am 19.04.2021

• An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT

  sciencedirect.com, hinzugefügt am 19.04.2021

• Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

  medrxiv.org, hinzugefügt am 18.04.2021

• General Principles of COVID-19 Vaccines for Immunocompromised Patients

  hematology.org, hinzugefügt am 17.04.2021

• People With Blood Cancer May Not Be Optimally Protected After mRNA COVID-19 Vaccination

  scitechdaily.com, hinzugefügt am 17.04.2021

• People With Blood Cancer May Not Be Optimally Protected After mRNA COVID-19 Vaccination

  nytimes.com, hinzugefügt am 17.04.2021

• Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

  immunology.sciencemag.org, hinzugefügt am 17.04.2021

• Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

  medrxiv.org, hinzugefügt am 08.04.2021

• NEUARTIGER IMPFSTOFF ZUR AKTIVIERUNG VON T-ZELL-ANTWORTEN GEGEN SARS-COV-2 IN ERPROBUNG – IMPFSTUDIE STARTET

  dgfi.org, hinzugefügt am 08.04.2021

• Rheumatologen aktualisieren Empfehlungen zu Therapie und COVID-19-Impfung

  aerzteblatt.de, hinzugefügt am 06.04.2021

• COVID-19 and Indolent Lymphomas: Frequently Asked Questions

  hematology.org, hinzugefügt am 06.04.2021

• What information is there on COVID-19 vaccination?

  rheumatology.org.uk, hinzugefügt am 06.04.2021

Keine Quelle enthält diesen Text.